Work

1199TiP Phase I trial of in situ vaccination with autologous CCL21-modified dendritic cells (CCL21-DC) combined with pembrolizumab for advanced NSCLC

Year: 2022

Type: article

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2022.07.1875

Institution: University of California, Los Angeles

Language: English

Topic: Immunotherapy and Immune Responses

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Pfizer, GlaxoSmithKline, Spectrum Pharmaceuticals, Symphogen

OpenAlex ID: W4295837132

FWCI:

Cites: 1

Cited by:

Related to: 10